These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 15343347)

  • 1. Defective blood dendritic cells in chronic myeloid leukemia correlate with high plasmatic VEGF and are not normalized by imatinib mesylate.
    Boissel N; Rousselot P; Raffoux E; Cayuela JM; Maarek O; Charron D; Degos L; Dombret H; Toubert A; Rea D
    Leukemia; 2004 Oct; 18(10):1656-61. PubMed ID: 15343347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imatinib and plasmacytoid dendritic cell function in patients with chronic myeloid leukemia.
    Mohty M; Jourdan E; Mami NB; Vey N; Damaj G; Blaise D; Isnardon D; Olive D; Gaugler B
    Blood; 2004 Jun; 103(12):4666-8. PubMed ID: 14715630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imatinib mesylate (STI-571) reduces Bcr-Abl-mediated vascular endothelial growth factor secretion in chronic myelogenous leukemia.
    Ebos JM; Tran J; Master Z; Dumont D; Melo JV; Buchdunger E; Kerbel RS
    Mol Cancer Res; 2002 Dec; 1(2):89-95. PubMed ID: 12496355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effects of ST1571 on the development of dendritic cells derived from bone marrow mononuclear cells in patients with chronic myeloid leukemia].
    Zheng SE; Jin J; Tong XM; Qian WB; Xue YQ
    Zhonghua Zhong Liu Za Zhi; 2006 Dec; 28(12):920-3. PubMed ID: 17533744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interferon decreases VEGF levels in patients with chronic myeloid leukemia treated with imatinib.
    Legros L; Guilhot J; Huault S; Mahon FX; Preudhomme C; Guilhot F; Hueber AO;
    Leuk Res; 2014 Jun; 38(6):662-5. PubMed ID: 24553365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo effects of imatinib mesylate on human haematopoietic progenitor cells.
    Agis H; Jaeger E; Doninger B; Sillaber C; Marosi C; Drach J; Schwarzinger I; Valent P; Oehler L
    Eur J Clin Invest; 2006 Jun; 36(6):402-8. PubMed ID: 16684124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Normal intrinsic Th1/Th2 balance in patients with chronic phase chronic myeloid leukemia not treated with interferon-alpha or imatinib.
    Kiani A; Habermann I; Schäke K; Neubauer A; Rogge L; Ehninger G
    Haematologica; 2003 Jul; 88(7):754-61. PubMed ID: 12857553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased IFN-gamma synthesis by T cells from patients on imatinib therapy for chronic myeloid leukemia.
    Aswald JM; Lipton JH; Aswald S; Messner HA
    Cytokines Cell Mol Ther; 2002; 7(4):143-9. PubMed ID: 14660054
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.
    Hughes TP; Kaeda J; Branford S; Rudzki Z; Hochhaus A; Hensley ML; Gathmann I; Bolton AE; van Hoomissen IC; Goldman JM; Radich JP;
    N Engl J Med; 2003 Oct; 349(15):1423-32. PubMed ID: 14534335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Efficacy of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, on chronic myeloid leukemia in blast phase].
    Zhang GC; Zheng D; Li QH; Li XH; Cai CC; Luo SK; Li J; Peng AH; Tong XZ; Tan EX; Hong WD
    Ai Zheng; 2004 Dec; 23(12):1696-9. PubMed ID: 15601563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Monitoring bcr/abl mRNA levels in imatinib mesylate treated chronic myeloid leukemia patients by real-time quantitative RT-PCR].
    Qin YZ; Ruan GR; Liu YR; Li JL; Fu JY; Wang H; Chang Y; Jiang B; Jiang Q; Jiang H; Qiu JY; Chen SS; Lu DP
    Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):1-5. PubMed ID: 15946498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Psoriasis vulgaris exacerbated by imatinib therapy in chronic myelogenous leukemia].
    Shimizu K; Kuroda H; Kida M; Watanabe H; Shirao S; Akiyama T; Fujimi A; Tanaka I; Sato T; Matsunaga T; Niitsu Y
    Rinsho Ketsueki; 2005 Oct; 46(10):1152-5. PubMed ID: 16440780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imatinib mesylate does not impair the immunogenicity of human myeloid blood dendritic cells.
    Wehner R; Wendisch M; Schäkel K; Bornhäuser M; Platzbecker U; Mohr B; Temme A; Bachmann M; Rieber EP; Schmitz M
    Leukemia; 2006 Sep; 20(9):1629-32. PubMed ID: 16838025
    [No Abstract]   [Full Text] [Related]  

  • 14. Acute myeloid leukemia developing during imatinib mesylate therapy for chronic myeloid leukemia in the absence of new cytogenetic abnormalities.
    Pawarode A; Sait SN; Nganga A; Coignet LJ; Barcos M; Baer MR
    Leuk Res; 2007 Nov; 31(11):1589-92. PubMed ID: 17391756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imatinib mesylate minimally affects bcr-abl+ and normal monocyte-derived dendritic cells but strongly inhibits T cell expansion despite reciprocal dendritic cell-T cell activation.
    Boissel N; Rousselot P; Raffoux E; Cayuela JM; Soulier J; Mooney N; Charron D; Dombret H; Toubert A; Rea D
    J Leukoc Biol; 2006 Apr; 79(4):747-56. PubMed ID: 16461746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML).
    Walz C; Sattler M
    Crit Rev Oncol Hematol; 2006 Feb; 57(2):145-64. PubMed ID: 16213151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative gene expression profile of chronic myeloid leukemia cells innately resistant to imatinib mesylate.
    Tipping AJ; Deininger MW; Goldman JM; Melo JV
    Exp Hematol; 2003 Nov; 31(11):1073-80. PubMed ID: 14585372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dendritic cells become BCR-ABL negative in chronic myeloid leukaemia patients successfully treated with imatinib.
    Wang L; Butt NM; Atherton MG; Clark RE
    Leukemia; 2004 May; 18(5):1025-7. PubMed ID: 15014531
    [No Abstract]   [Full Text] [Related]  

  • 19. Successful peripheral blood stem cell mobilisation with filgrastim in patients with chronic myeloid leukaemia achieving complete cytogenetic response with imatinib, without increasing disease burden as measured by quantitative real-time PCR.
    Hui CH; Goh KY; White D; Branford S; Grigg A; Seymour JF; Kwan YL; Walsh S; Hoyt R; Trickett A; Rudzki B; Ma DD; To LB; Hughes TP
    Leukemia; 2003 May; 17(5):821-8. PubMed ID: 12750692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sensitivity to imatinib therapy may be predicted by testing Wilms tumor gene expression and colony growth after a short in vitro incubation.
    Cilloni D; Messa F; Gottardi E; Fava M; Arruga F; Defilippi I; Carturan S; Messa E; Morotti A; Giugliano E; Rege-Cambrin G; Alberti D; Baccarani M; Saglio G
    Cancer; 2004 Sep; 101(5):979-88. PubMed ID: 15329907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.